<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02550964</url>
  </required_header>
  <id_info>
    <org_study_id>2013-0826</org_study_id>
    <nct_id>NCT02550964</nct_id>
  </id_info>
  <brief_title>Incidence and Risk Factor of Hydroxychloroquine and Chloroquine Retinopathy</brief_title>
  <official_title>Incidence and Risk Factor Evaluation for Toxic Maculopathy Associated With Hydroxychloroquine and Chloroquine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the incidence and risk factor of toxic maculopathy
      who treated with hydroxychloroquine or chloroquine due to their autoimmune disease such as
      rheumatoid arthritis or systemic lupus erythematosus. Total 5-year of the study periods, the
      investigators will screen these patients by baseline examination (Fundus photography, fundus
      autofluorescence, spectral-domain optical coherence tomography, Humphrey visual field test
      and multifocal electroretinography) and observe with same examination for every year.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of toxic maculopathy associated with HCQ or CQ</measure>
    <time_frame>1 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Risk factor of HCQ/CQ retinopathy</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characteristics and type of HCQ/CQ retinopathy (parafoveal or pericentral retinopathy)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression of retinopathy after drug cessation</measure>
    <time_frame>1 years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">124</enrollment>
  <condition>Toxic Maculopathy</condition>
  <arm_group>
    <arm_group_label>HCQ/CQ</arm_group_label>
    <description>Patients who treated with HCQ(Hydroxychloroquine) or CQ(Chloroquine) for autoimmune diseases such as Rheumatoid arthritis(RA), systemic lupus erythematosus(SLE) will be recruited, and get the composite examination for toxic maculopathy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Composite Examination</intervention_name>
    <description>First, patients will get the baseline ophthalmologic exam and medical evaluation by physicians. As a diagnostic method, the composite examination including fundus photography, fundus autofluorescence, spectral-domain optical coherence tomography, Humphrey visual field test and multifocal electroretinography will be tested once every year.</description>
    <arm_group_label>HCQ/CQ</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The purpose of this cohort study is to evaluate the incidence and risk factor. We will
        recruit a total of 124 participants considering the study budget.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient who treated with HCQ or CQ due to autoimmune diseases such as RA, SLE

          -  Patient who did not previously diagnosed with HCQ/CQ toxic retinopathy

        Exclusion Criteria:

          -  Aged less than 19 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JooYong Lee, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>JooYong Lee</last_name>
    <phone>+82-2-3010-3976</phone>
    <email>ophthalmo@amc.seoul.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Byung-gil Moon</last_name>
    <phone>+82-2-3010-1862</phone>
    <email>eye82eye@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JooYong Lee, Professor</last_name>
      <phone>+82-2-3010-3976</phone>
      <email>ophthalmo@amc.seoul.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2015</study_first_submitted>
  <study_first_submitted_qc>September 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2015</study_first_posted>
  <last_update_submitted>September 17, 2015</last_update_submitted>
  <last_update_submitted_qc>September 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>JooYong Lee</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Autoimmune Disease</keyword>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>Systemic Lupus Erythematosus</keyword>
  <keyword>Hydroxychloroquine(HCQ)</keyword>
  <keyword>Chloroquine(CQ)</keyword>
  <keyword>Toxic Maculopathy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chloroquine</mesh_term>
    <mesh_term>Chloroquine diphosphate</mesh_term>
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

